The Oncology Institute Warrant
TOIIW
TOIIW was delisted on the 31st of July, 2026.
12 hedge funds and large institutions have $818K invested in The Oncology Institute Warrant in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
319% more capital invested
Capital invested by funds: $195K → $818K (+$623K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
9% more funds holding
Funds holding: 11 → 12 (+1)
4.28% less ownership
Funds ownership: 4.28% → 0% (-4.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$11.4K |
| 2 |
FL
FreeGulliver LLC
New Orleans,
Louisiana
|
+$8.79K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$622 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$187 |
TOIIW Hedge Fund Activity: Q3 2025 in Review
12 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in The Oncology Institute Warrant (TOIIW) for Q3 2025, worth a combined $818K — up 319% from $195K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TOIIW positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Oasis Management Company, opening a new position worth an estimated $11.4K. The largest seller was UBS Group, exiting entirely with an estimated $187 sold.
- 12 institutional investors held The Oncology Institute Warrant (TOIIW) as of Q3 2025, up from 11 in Q2 2025.
- Funds reported $818K of The Oncology Institute Warrant stock for Q3 2025, up 319% quarter-over-quarter.
- 2 funds opened new The Oncology Institute Warrant positions in Q3 2025 and 1 closed out, a net change of +1 holder.
- The largest The Oncology Institute Warrant buyer in Q3 2025 was Oasis Management Company, an estimated $11.4K added.
- The largest The Oncology Institute Warrant seller in Q3 2025 was UBS Group, an estimated $187 sold.
Based on aggregated 13F filings for Q3 2025.